0001493152-26-013664
SEC filingFY2025 saw Akari Therapeutics deliver narrowed operating and net losses via targeted cost reductions, with core focus on advancing its lead AKTX-101 pipeline program.
For fiscal 2025, Akari delivered a narrowed GAAP operating loss relative to the prior fiscal year, driven by two core cost reduction actions outlined by management. First, the company’s May 2024 workforce reduction, paired with lower consultant costs, delivered measurable decreases in operating expenses year over year. Second, the suspension of the legacy AK901 clinical program and pre-clinical PAS-nomacopan program, coupled with the company’s decision to seek external partners for further development of these assets, further reduced expenditure levels in the period. The company’s net loss also narrowed year over year in fiscal 2025, with non-cash charges and working capital adjustments contributing to the difference between operating and net loss trends. Exchange rate fluctuations may contribute to period-over-period variability in reported results, due to the timing and volume of foreign currency denominated expenditures and payments.
Net cash used in operating activities was lower in fiscal 2025 than in the prior year, consistent with the company’s reduced loss profile. Cash used in operations consists primarily of reported net loss adjusted for non-cash charges and working capital changes, per management’s disclosures. The company expects to continue generating substantial operating losses for the foreseeable future, as it invests in core pipeline activities and covers general and administrative costs. Significant additional capital will be required to fund planned operations going forward; if acceptable capital raising terms are not available when needed, the company may face material adverse impacts to its business, operating results, and long-term prospects.
Management’s near-term operational strategy remains centered on advancing its lead program, AKTX-101, through IND-enabling activities and clinical readiness. The company also intends to maintain flexibility to expand its PH1-based ADC pipeline as capital levels and strategic priorities allow. All summary disclosures are high-level, and investors are directed to the full “Financial Condition, Liquidity and Capital Resources” section of the 10-K for additional detail on performance and operational plans.